Regeneron Pharmaceuticals


Want a discount? Become a member by purchasing Annual Subscription!
SKU: REGN Category:


Regeneron delivered an all-around beat in the previous quarter, demonstrating progress toward their long-term objective of business growth and revenue diversification. Total revenues saw an 11% increase compared to the previous year’s quarter, primarily driven by collaboration revenues with Sanofi and net product sales of Libtayo, which exhibited impressive growth of 39% and 49%, respectively. Notably, non-EYLEA revenue contributions accounted for 41% of total revenues, marking a significant proportion, the highest in the last decade, excluding contributions from COVID-19 antibodies. Regeneron provided an update on the FDA’s Complete Response Letter (CRL) related to aflibercept 8 milligrams, emphasizing that the CRL was solely based on observations stemming from a third-party contract manufacturing organization’s FDA inspection, specifically Catalent. These observations concerned production and process control procedures, equipment validation, and facility maintenance. Collaboration between Regeneron, Catalent, and the FDA is ongoing, aiming to address the noted observations and resume BLA approvals. Regeneron reiterated confidence in its strategic approach, emphasizing investment in internal R&D capabilities and potential collaborations while maintaining a commitment to delivering medical breakthroughs and shareholder value.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!